Skip to content
The BCI Briefing

Company profileNeuroprosthetic

MED-EL

One of the makers of the cochlear implant, the most widely used neural prosthesis.

Location
Innsbruck, Austria
Founded
1990
Class
NeuroprostheticHearing implants write sound to the auditory nerve. Nothing is decoded from the brain, so it is not counted as a BCI company.Not counted among core BCI companies.
Website
medel.com
Sources last checked
7 Oct 2026

What they are building

Innsbruck company founded by Ingeborg and Erwin Hochmair. It makes cochlear implants, auditory brainstem implants, systems that combine electric and acoustic stimulation, and middle-ear and bone-conduction implants.

Signal
Cochlear: Electrical pulses along an array ordered by pitchABI: Electrical pulses across a paddle of disc electrodes
Invasiveness
Invasive
Recording / stimulation
Stimulation
Device
SYNCHRONY ABI — Implant with a paddle of electrode contacts laid on the cochlear nucleus of the brainstem
Channels
12 contacts
Regulatory status
CE marked from 12 months of age, according to the company; its page for clinicians mentions no approval in the United States
Main use cases
Hear

Where they are clinically

Approved / cleared

Authorised by a regulator for a defined use. Always check the scope.

Cochlear implants are on the market and are routine care. Most of the studies registered under the company's name concern fitting and outcomes. Its auditory brainstem implant is CE marked, according to the company; its page for clinicians mentions no approval in the United States.

Access today

Available

Authorised and obtainable for a defined group of patients or users.

Shown in people
Hearing through an implant in routine care; the registry returns 72 studies under the company's name. In September 2026 it launched in Europe a CE-marked implant with every part under the skin, the microphone included.
Still an aim
Approval of that totally implanted system in the United States, where it is not available.
What stands in the way
It writes and does not read: nothing about the listener comes back from the implant.

On record here: 0 peer-reviewed papers

Why this company matters

MED-EL is in this directory as a reference point. The cochlear implant is the neural interface that became standard care: routine surgery, reimbursement, decades of follow-up. Every implanted BCI faces questions it has already had to answer, about fitting each user, supporting a device for life and replacing it. It also marks the limit of the comparison: it writes a signal the brain learns to use and reads nothing back.

Key milestones

  1. 29 Sep 2026

    Company launches TICI UNICO in Europe with a CE mark: a cochlear implant with no external part. It is not approved in the United States.

    MED-EL (press release)

  2. 18 Apr 2018

    Company reports a CE mark widened for its auditory brainstem implant: from people aged 15 and over with neurofibromatosis type 2 to people from 12 months of age whose auditory nerve does not work.

    MED-EL Professionals Blog

  3. 1990

    Ingeborg and Erwin Hochmair hire the company's first staff in Innsbruck. Their multichannel cochlear implant was first implanted in 1977, according to the company.

    MED-EL

Competitive context

Sources

  1. 01

    MED-EL corporate information (opens in a new tab)

    Company reportedMED-ELChecked against source 6 Oct 2026

    Names the founders and lists the implant types the company makes. It gives no founding year or headcount.

  2. 02

    Meet the woman behind the modern-day cochlear implant: Ingeborg Hochmair (opens in a new tab)

    Company reportedMED-ELChecked against source 6 Oct 2026

    States that the company hired its first staff in Innsbruck in 1990 and that the founders' multichannel implant was first implanted in 1977.

  3. 03

    Expanded candidacy: auditory brainstem implants (opens in a new tab)

    Company reportedMED-EL Professionals Blog18 Apr 2018Checked against source 7 Oct 2026

    The company's page for clinicians. Names the SYNCHRONY Auditory Brainstem Implant System and its 12-electrode paddle, and reports a CE mark widened from people aged 15 and over with neurofibromatosis type 2 to people from 12 months of age with a non-functional auditory nerve. It mentions no FDA approval.

  4. 04

    ClinicalTrials.gov: studies naming MED-EL as sponsor or collaborator (opens in a new tab)

    Clinical registryClinicalTrials.govChecked against source 6 Oct 2026

    72 studies returned for the name on 6 October 2026, under several legal entities.

  5. 05

    MED-EL launches TICI UNICO, a totally implanted cochlear implant (opens in a new tab)

    Company reportedMED-EL (press release)29 Sep 2026Checked against source 6 Oct 2026

    The company's release: CE mark and launch in Europe; every component, the microphone included, is implanted; not approved by the FDA. We repeat no claim of being first.